NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA




PRESS RELEASE
Lyon, December 4th, 2025




ADOCIA Announces the Completion of a €10 Million
Fundraising

• Fundraising of a total amount of €10 million in gross proceeds through the issuance of a
total number of 1,262,626 new shares, each with one share warrant attached, subscribed
by CVI Investments, Inc.

• Settlement-delivery of the new shares and share warrants expected on December 8, 2025

• Proceeds from the fundraising to support continued development of Adocia’s proprietary
technology platforms

• Cash runway extended to beginning 2027


7:30 am CET - Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage
biopharmaceutical company focused on the research and development of innovative therapeutic solutions for
the treatment of diabetes and obesity, announces today the successful completion of a capital increase of a total
gross amount of €10 million subscribed by CVI Investments, Inc. (the “Reserved Offering”).


“We would like to thank CVI Investments, Inc., a well-recognized institutional investor in Europe and the US, for this
€10 million capital increase that extends our cash runway to beginning 2027. It also gives us the means to accelerate
our growth, notably by investing in the industrialization of our BioChaperone® technology and in innovation through
our new long-acting peptide platform, AdoXLongTM”, declares Olivier Soula, CEO and co-founder of Adocia.




1
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA




Use of proceeds
The Company intends to use the net proceeds of the Reserved Offering to finance its strategic roadmap and
working capital requirements:

• approximately 50% of the amount raised for the development of AdoXLongTM platform, with an initial
application on a monthly injectable semaglutide formulation, and

• approximately 30% of the amount raised for the development of industrial-scale manufacturing
processes for BioChaperone®, and

• approximately 20% of the amount raised to finance its working capital requirements.



As of September 30, 2025, the Company's cash position amounted to €13.4 million, enabling the Company to
finance its activities until Q2 2026, it being specified that this cash horizon does not take into account any
revenue that may be generated by future partnerships, nor the exercise of the warrants issued during the
February 2025 fundraising, which could generate up to €10.2 million if all of the warrants were exercised.
Considering the net proceeds of the Reserved Offering, the Company estimates that it will be able to finance its
activities until beginning 2027, it being specified that this cash horizon does not take into account the exercise
of the warrants issued in connection with the Reserved Offering, which could generate up to €11.5 million if all
of the warrants were exercised.



Terms and conditions of the Reserved Offering
The Reserved Offering, for a total amount of €9,999,997.92 (including share issue premium), was carried out
through the issuance of 1,262,626 new ordinary shares of the Company (the “New Shares”) each with one share
warrant attached (a “BSA” and, together with the New Share to which it is attached, an “ABSA”), at a price of
€7.92 per ABSA, in the context of a share capital increase with cancellation of shareholders’ preferential
subscription rights in favor of CVI Investments, Inc. The latter has confirmed that it qualifies under the category
defined by the Combined General Meeting of the Company’s shareholders of June 11, 2025, pursuant to its 21st
resolution, namely any natural or legal persons (including companies), trusts, and investment funds, or other
investment vehicles, regardless of their form (including, without limitation, any investment funds or venture
capital companies, in particular any FPCI, FCPI, or FIP), governed by French or foreign law, whether or not
shareholders of the Company, investing on a regular basis in the healthcare and/or biotechnology sector.

The Reserved Offering was made to qualified investors and/or a limited number of investors in Europe (including
France), outside France with the exception of the United States, Canada, South Africa, Australia, and Japan, in
the context of offshore transactions, as defined and in accordance with Regulation S of the Securities Act.

The issue of the ABSAs was decided on December 3rd, 2025 by the Company’s Chief Executive Officer, acting
pursuant to the sub-delegation of competence granted by the Company's Board of Directors on November 28,
2025, itself acting pursuant to the delegation of competence granted to it by the Combined General Meeting of
the Company’s shareholders of June 11, 2025, pursuant to its 21st resolution.




2
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA




Subscription price of the ABSAs
The issue price of each ABSA is equal to €7.92, corresponding to the Adocia share closing price of December 3rd,
2025, and representing a discount of 1.98% compared to the volume-weighted average price of the Adocia share
over the last three trading days preceding the setting of such issue price, i.e. December 1st, 2nd and 3rd, 2025,
which average is equal to €8.08 (the “3-day VWAP”).

The issue price of an ABSA minus the theoretical value of a BSA reflects a total discount of 14.75% per Adocia
share compared to the 3-day VWAP, consistent with the maximum discount authorized by the Combined
General Meeting of the Company’s shareholders of June 11, 2025, pursuant to its 21st resolution.

Terms and conditions of the BSAs
One BSA is attached to each New Share. One BSA entitles its holder to subscribe to one new ordinary share of
the Company at a price of €9.11 per ordinary share. The BSAs may be exercised at any time during the
forty-two (42) months following their issue. In the event that all BSAs are exercised, a total of 1,262,626
additional ordinary shares in the Company will be issued, representing total additional proceeds of approximately
€11.5 million. The theoretical value of each BSA, assuming volatility of 29.854%1 and based on the closing price
as of December 3rd 2025, is equal to €1.0320 according to the Black & Scholes model.

The BSAs will be immediately detached (détachés) from the New Shares upon issuance but will not be subject to
any listing application by the Company on any market.




Impact of the Reserved Offering on the Company’s
shareholding
Subject to the settlement-delivery of the Reserved Offering expected to occur on December 8, 2025, the
Company’s share capital will be €1,956,890.90, comprising 19,568,909 ordinary shares (or €2,083,153.50
comprising 20,831,535 ordinary shares in the event of exercise of all BSAs) with a par value of €0.10,
representing 6.90% of the total current share capital of the Company (or 13.79% in the event of exercise of all
BSAs).

To the Company’s knowledge, immediately prior to completion of the Reserved Offering, the breakdown of the
Company's share capital was as follows:




1
Based on the volatility of last 12 months of Biotech Index




3
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA




On a non-diluted basis On a diluted basis (1)

Number of % of theoretical Number of % of theoretical
% of capital % of capital
shares voting rights (2) shares voting rights (2)

Soula family 1,744,083 9.5% 15.9% 2,055,753 9.8% 15.4%

Gérard Soula 1,378,317 7.5% 12.6% 1,559,987 7.4% 11.9%

Olivier Soula 365,766 2.0% 3.3% 495,766 2.4% 3.5%

Financial investors 1,277,304 7.0% 8.1% 1,473,810 7.0% 8.1%

Vester Finance (3) 889,555 4.9% 4.4% 1,086,061 5.2% 4.7%

Amundi Funds 1,570 0.0% 0.0% 1,570 0.0% 0.0%

Viveris Fund 25,618 0.1% 0.3% 25,618 0.1% 0.2%

Oréo Finance 40,561 0.2% 0.4% 40,561 0.2% 0.4%

Relyens (4) 320,000 1.7% 3.1% 320,000 1.5% 2.8%

Employees 209,973 1.1% 1.4% 503,300 2.4% 2.5%

Scientific Committee (BSA) 700 0.0% 0.0% 15,700 0.1% 0.1%

Treasury shares (5) 14,472 0.1% 0.1% 14,472 0.1% 0.1%
(6)
Other shareholders 15,059,751 82.3% 74.5% 16,891,347 80.6% 73.9%

Total 18,306,283 100.0% 100.0% 20,954,382 100.0% 100.0%

(1) After the issue of a maximum total number of 2,648,099 new ordinary shares of the Company resulting from (i) the definitive acquisition of the 445,827 free shares
(actions gratuites) allotted by the Company and outstanding as at today, and (ii) the exercise of the 2,152,272 warrants (bons de souscription d’actions) (including
2,101,857 warrants alloted during the February 26, 2025 fundraising) and the 50,000 founder warrants (bons de souscription de parts de créateur d’entreprise –
“BSPCE”) alloted by the Company and outstanding as at today.
(2) Theoretical voting rights (i.e. including shares without voting rights). A voting right double that conferred on other shares, having regard to the proportion of the
share capital they represent, is attributed to all fully paid-up shares (whatever their category) for which proof is provided of having been nominatively registered for
at least two years in the name of the same shareholder.
(3) To the Company's knowledge, based on the information contained in the threshold crossing declaration filed by Vester Finance on October 20, 2025.
(4) Formerly known as "Société Hospitalière d’Assurance Mutuelles" (SHAM).
(5) Auto-control shares held under the liquidity contract with Kepler Capital Markets as at November 30, 2025.
(6) Including any bearer shares held by the Company’s historical financial investors.




To the Company’s knowledge, following settlement-delivery of the Reserved Offering, the breakdown of the
Company’s share capital is as follows:


On a non-diluted basis On a diluted basis (1)


Number of % of theoretical Number of % of theoretical
% of capital % of capital
shares voting rights (2) shares voting rights (2)


Soula Family 1,744,083 8.9% 14.9% 2,055,753 8.8% 14.6%

Gérard Soula 1,378,317 7.0% 11.8% 1,559,987 6.6% 11.3%

Olivier Soula 365,766 1.9% 3.1% 495,766 2.1% 3.3%

Financial investors 2,539,930 13.0% 13.5% 3,999,062 17.0% 12.8%

CVI Investments, Inc. 1,262,626 6.5% 5.8% 2,525,252 10.8% 5.2%

Vester Finance (3) 889,555 4.5% 4.1% 1,086,061 4.6% 4.5%

Amundi Funds 1,570 0.0% 0.0% 1,570 0.0% 0.0%

Viveris Funds 25,618 0.1% 0.2% 25,618 0.1% 0.2%

Oréo Finance 40,561 0.2% 0.4% 40,561 0.2% 0.3%




4
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA




Relyens (4) 320,000 1.6% 3.0% 320,000 1.4% 2.6%

Employees 209,973 1.1% 1.3% 503,300 2.1% 2.4%

Scientific Committee (BSA) 700 0.0% 0.0% 15,700 0.1% 0.1%

Treasury shares (5) 14,472 0.1% 0.1% 14,472 0.1% 0.1%

Other shareholders (6) 15,059,751 77.0% 70.2% 16,891,347 71.9% 70.0%

Total 19,568,909 100.0% 100.0% 23,479,634 100.0% 100.0%

(1) After the issue of a maximum total number of 2,648,099 new ordinary shares of the Company resulting from (i) the definitive acquisition of the 445,827 free shares
(actions gratuites) allotted by the Company and outstanding as at today, and (ii) the exercise of the 2,152,272 warrants (bons de souscription d’actions) (including
2,101,857 warrants alloted during the February 26, 2025 fundraising) and the 50,000 founder warrants (bons de souscription de parts de créateur d’entreprise –
“BSPCE”) alloted by the Company and outstanding as at today, and (iii) the exercise of the 1,262,626 BSA issued in connection with the Reserved Offering.
(2) Theoretical voting rights (i.e. including shares without voting rights). A voting right double that conferred on other shares, having regard to the proportion of the
share capital they represent, is attributed to all fully paid-up shares (whatever their category) for which proof is provided of having been nominatively registered for
at least two years in the name of the same shareholder.
(3) To the Company's knowledge, based on the information contained in the threshold crossing declaration filed by Vester Finance on October 20, 2025.
(4) Formerly known as "Société Hospitalière d’Assurance Mutuelles" (SHAM).
(5) Auto-control shares held under the liquidity contract with Kepler Capital Markets as at November 30, 2025.
(6) Including any bearer shares held by the Company’s historical financial investors.




On the basis of the share capital of the Company immediately after completion of the Reserved Offering, the
interest of a shareholder who held 1.00% of the Company’s share capital prior to the completion of the Reserved
Offering and who did not subscribe to it now stands at 0.935% on a non-diluted basis and 0.824% on a diluted
basis, as set out in the table below.

Portion of consolidated
shareholders' equity per share Ownership interest in %
(EUR)
Non-diluted basis Diluted basis(1) Non-diluted basis Diluted basis(1)
Before the issuance of the New Shares (0.03) (0.03) 1.000% 0.874%
After the issuance of the New Shares (0.03) (0.03) 0.935% 0.824%
After the issuance of the New Shares and the shares that may
(0.03) (0.03) 0.879% 0.780%
result from the exercise of the BSA

(1) After the issue of a maximum total number of 2,648,099 new ordinary shares of the Company resulting from (i) the definitive acquisition of the 445,827 free shares
(actions gratuites) allotted by the Company and outstanding as at today, and (ii) the exercise of the 2,152,272 warrants (bons de souscription d’actions) (including
2,101,857 warrants alloted during the February 26, 2025 fundraising) and the 50,000 founder warrants (bons de souscription de parts de créateur d’entreprise –
“BSPCE”) alloted by the Company and outstanding as at today.




Prospectus
The Reserved Offering is not subject to a prospectus requiring an approval from the French Financial Market
Authority (Autorité des Marchés Financiers) (the “AMF”). In accordance with Regulation (EU) 2017/1129 of the
European Parliament and of the Council of June 14, 2017, as amended (the “Prospectus Regulation”), the
Company has today filed with the AMF a document containing the information set out in Annex IX of the
Prospectus Regulation (the “Information Document”), copies of which are available free of charge on the
Company's website at https://www.adocia.com/investors/. It is specified that the Information Document has
not been subject to the review and approval of the AMF. The investors are advised not to make any investment
decisions based solely on the information contained in the Information Document.




5
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA




Admission to trading of the New Shares
The New Shares are expected to be listed on the regulated market of Euronext Paris on December 8, 2025.

The New Shares will be subject to the provisions of the Company’s bylaws and will be assimilated to existing
shares upon final completion of the Reserved Offering. They will bear current dividend rights and will be admitted
to trading on the same listing line as the Company’s existing shares under the same ISIN code FR0011184241-
ADOC.




Standstill and lock-up commitments
In the context of the Reserved Offering, the Company has signed a standstill commitment for a period of 90
calendar days following the date of settlement-delivery of the Reserved Offering, subject to certain customary
exceptions, limiting, in particular, the Company's ability to issue new shares during said period.

The directors of the Company and its CFO-COO, Mathieu-William Gilbert, have signed a lock-up commitment
for a period of 90 calendar days following the date of settlement-delivery of the Reserved Offering, in respect
of their entire shareholding in the Company's share capital, representing, in particular, for the Chairman, the
Chief Executive Officer and the CFO-COO of the Company, respectively, 7.04%, 1.87% and 0.01% of the
Company's share capital (on a non-diluted basis and post-Reserved Offering), subject to certain customary
exceptions.




Financial intermediaries
Stifel Europe Securities SAS and Stifel Europe Limited Paris Branch (together, “Stifel”) acted as Sole Global
Coordinator and Sole Bookrunner. The Reserved Offering was subject to an investment agreement entered into
between the Company and Stifel.




Risk factors
The risk factors relating to the Company are set out in in section 1.4 of the Company’s universal registration
document filed with the AMF under number D. 25-0330 on April 29, 2025, and section 1.4 of the Company’s
2025 Half-Year financial report, as updated by the Information Document. These documents are available free
of charge on the Company’s website at https://www.adocia.com/investors/ and on the AMF’s website at
www.amf-france.org.

Investors are also advised to consider the following risks specific to the Reserved Offering: (i) the market price
of the Company's shares could fluctuate and fall below the subscription price of the ABSAs issued as part of the
Reserved Offering, (ii) the volatility and liquidity of the Company’s shares may fluctuate significantly, (iii) sales of
the Company’s shares may occur on the market and negatively impact the Company’s share price, (iv) the
Company’s shareholders who did not participate in the Reserved Offering could suffer potentially significant
dilution resulting from the potential exercise of the BSAs and, more generally, any future capital increases made
necessary by the Company’s search for financing.




6
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA




About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the
field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1)
BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral ®, an
oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an
initial application in pancreatic cells transplantation; and 4) AdoXLong TM, a long-acting peptide platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed
on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).




Contact

Adocia Ulysse Communication
Olivier Soula Adocia Press & Investor Relations
CEO Bruno Arabian
Nicolas Entz

+33 (0)4 72 610 610 adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26
www.adocia.com




Disclaimer
This press release does not constitute or form a part of any offer or the solicitation to purchase or subscribe for
securities in the United States of America, Canada, Australia, South Africa or Japan and may not be published,
forwarded or distributed, directly or indirectly, in any of these countries.

This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129
of the European Parliament and of the Council of June 14, 2017, as amended (the “Prospectus Regulation”).

In France, the offer of the Company’s shares described above has been made exclusively in the context of (i) a
capital increase reserved to the category of beneficiaries, pursuant to Article L. 225-138 of the French
commercial code, defined in the twenty-first resolution of the Company’s combined shareholders’ meeting held
on June 11, 2025. It shall not constitute a public offering requiring the publication of a prospectus to be approved
by the AMF. A document containing the information required by Annex IX of the Prospectus Regulation has
been prepared in connection with the listing of the Company’s shares issued in the context of the offer and the
shares that may be issued upon exercise of the share warrants issued in the context of the offer (the “Information




7
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA



Document”), of which copies may be obtained free of charge at the Company’s headquarter (115, avenue
Lacassagne, 69003 Lyon, France) or on its website (www.adocia.com/investors/).

The Company draws the public’s attention to the risk factors set out in Section 1.4 of the Company’s Universal
Registration Document filed with the AMF on 29 April 2025 under number D.25-0330, in Section 1.4 of the
Company’s 2025 half-year financial report, as updated in Section VIII “Issuer-Specific Risk Factors” of the
Information Document.

With respect to Member States of the European Economic Area other than France, no action has been taken or
will be taken to permit a public offering of the securities referred to in this press release requiring the publication
of a prospectus or a document which would include the information required by Annex IX of the Prospectus
Regulation in any such Member State. Therefore, such securities may not be and shall not be offered in any
Member State other than France, except in accordance with the exemptions of the Prospectus Regulation (in
particular its 1(4)), not requiring the publication of a prospectus under Article 3 of the Prospectus Regulation or
an information document pursuant to Articles 1(4) and 1(5) of the Prospectus Regulation and/or any other similar
documentation in accordance with the applicable regulations in such Member State.

With respect to the United Kingdom, this press release and the information it contains are being distributed to
and are only intended for persons who are qualified investors (as defined in the Prospectus Regulation as it forms
part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) (the “UK Prospectus
Regulation”) and are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities and other such
persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies”, “unincorporated
associations”, etc.) or (iii) other persons to whom an invitation or inducement to participate in investment activity
(within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be
communicated or caused to be communicated (all such persons together being referred to as “Relevant
Persons”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this
press release relates will only be engaged with Relevant Persons. Any person who is not a Relevant Person
should not act or rely on this press release or any of its contents. This press release has been prepared on the
basis that any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this
press release relates will be made pursuant to an exemption under the UK Prospectus Regulation from the
requirement to publish a prospectus for offers of securities. This press release is not a prospectus for the
purposes of the UK Prospectus Regulation.

This press release and the information contained therein does not, and will not, constitute an offer to subscribe
or purchase, or a solicitation of an order to purchase or subscribe for, securities of the Company in the United
States or any other jurisdiction in which such transaction may be subject to restrictions. Securities may not be
offered, subscribed, or sold in the United States absent registration or an exemption from registration under the
U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), except pursuant to an exemption from, or in
a transaction not subject to, the registration requirements thereof and in compliance with applicable laws, it
being specified that the securities of the Company have not been and will not be registered under the U.S.
Securities Act, and the Company does not intend to make a public offer of its securities in the United States.

The dissemination, publication, or distribution of this press release in certain countries may constitute a violation
of applicable laws. Neither this press release nor any copy of it may be published, taken or transmitted, directly
or indirectly, within the territory of the United States (as that term is defined in Regulation S under the Securities
Act). Neither this press release nor any copy of it may be published, taken or transmitted, directly or indirectly,
in Australia, Canada, South Africa or Japan or to any person in any of those jurisdictions. This document does
not constitute an offer to sell or a public offering of the Company's securities in the United States or in any other
country.

MIFID II Product Governance/Target Market: Any person subsequently offering, selling or recommending the
shares of Adocia (a “distributor”) should take into consideration the type of clients assessment; however, a
distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the
shares of Adocia and determining appropriate distribution channels.




8
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,
JAPAN AND SOUTH AFRICA



The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions.
Any person who comes into possession of this press release must inform him or herself of and comply with any
such restrictions.

Any decision to subscribe for or purchase the shares or other securities of the Company must be made solely
based on information publicly available about the Company. Such information is not the responsibility of Stifel
and has not been independently verified by Stifel.




9